NCT00719121

Study on Anti-inflammatory Effects of Topical R115866 Gel

Placebo-Controlled, Investigator Blinded, Explorative Trial to Evaluate the Anti-inflammatory Effect of Multiple Topical Applications of R115866 Gel (0.35%) in Two Models of Cutaneous Inflammation in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Stiefel, a GSK Company · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this exploratory trial is to assess the anti-inflammatory effect(s) of topical R115866 in a model of UVB-induced inflammation and in a model of cutaneous irritation.

Conditions

• Cutaneous Inflammation

Interventions

Type	Name	Description
DRUG	Talarozole	Topical Application (20 mg)
DRUG	Differin™, 0.1% adapalene gel	Topical Application (20 mg)

Timeline

• Start date: 2006-11-01
• Primary completion: 2006-12-01
• Completion: 2007-03-01
• First posted: 2008-07-21
• Last updated: 2011-09-26

Locations

1 site across 1 country: Belgium